Trinity Biotech (TRIB) Cash from Operations (2021 - 2024)

Trinity Biotech has disclosed Cash from Operations across 4 years of filings, most recently posting 3583000.0 for Q4 2024.

• Cash from Operations for Q4 2024 came in at 3583000.0, up 1055.81% year-over-year; the trailing twelve-month figure through Dec 2024 was 26000.0 (up 99.43% YoY), and the FY2025 annual result was 5583000.0, down 33.21% from the prior year.
• Cash from Operations came in at 3583000.0 for Q4 2024 at Trinity Biotech, up from 3915683.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 3910000.0 in Q4 2021 to a low of 7128695.0 in Q2 2023.
• The 4-year median for Cash from Operations is 153341.5 (2023), against an average of 120500.0.
• Across the five-year window, Cash from Operations tumbled 86.45% in 2023 and surged 1055.81% in 2024, its largest moves.
• Trinity Biotech's Cash from Operations stood at 3910000.0 in 2021, then tumbled by 41.51% to 2287000.0 in 2022, then sank by 86.45% to 310000.0 in 2023, then soared by 1055.81% to 3583000.0 in 2024.
• The last three Cash from Operations figures came in at 3583000.0 (Q4 2024), 3915683.0 (Q2 2024), and 3317.0 (Q1 2024), per Business Quant data.